Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
  • 0 views
  • 29 Apr, 2022
  • 71 locations
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

treatment and remission gets shorter after each line of treatment. This is a study to determine recommended Phase 2 dose and change in disease symptoms of eftozanermin alfa in combination with bortezomib

cancer
refractory multiple myeloma
measurable disease
dexamethasone
bortezomib
  • 0 views
  • 15 May, 2022
  • 18 locations
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel

erythropoietin
dexamethasone
lenalidomide
human chorionic gonadotropin
chemotherapy regimen
  • 3 views
  • 30 Apr, 2022
  • 69 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

>Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete Arm 4: Selinexor

immunomodulatory imide drug
serum proteins
monoclonal protein
refractory multiple myeloma
line of therapy
  • 57 views
  • 19 Apr, 2022
  • 18 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide

high dose chemotherapy
dexamethasone
cell transplantation
velcade
lenalidomide
  • 14 views
  • 10 May, 2022
  • 34 locations
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

administration of Bortezomib in patients with B-precursor ALL with initial WBC100,000/l will improve treatment outcome? Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL

childhood all
adult t-cell leukemia/lymphoma
dexamethasone
lymphoid leukemia
daunorubicin
  • 179 views
  • 23 Jan, 2021
  • 59 locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the

vincristine
mercaptopurine
doxorubicin
adult t-cell leukemia/lymphoma
cyclophosphamide
  • 870 views
  • 13 Feb, 2022
  • 93 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

lymphoblastic leukemia (B-ALL) or B-lymphoblastic lymphoma (B-LLy), and the proteasome inhibitor bortezomib for those lacking targetable lesions. To improve overall treatment outcome of T acute

vincristine
cancer
vorinostat
consolidation therapy
mercaptopurine
  • 278 views
  • 11 May, 2022
  • 7 locations
International Study for Treatment of High Risk Childhood Relapsed ALL 2010

The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.

  • 34 views
  • 05 Mar, 2022
  • 10 locations
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)

A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.

  • 5 views
  • 18 May, 2022
  • 56 locations